60
Participants
Start Date
September 17, 2012
Primary Completion Date
August 16, 2017
Study Completion Date
December 5, 2018
turoctocog alfa
Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
Novo Nordisk Investigational Site, Budapest
Novo Nordisk Investigational Site, København Ø
Novo Nordisk Investigational Site, Linz
Novo Nordisk Investigational Site, Debrecen
Novo Nordisk Investigational Site, Innsbruck
Novo Nordisk Investigational Site, Graz
Novo Nordisk Investigational Site, Belgrade
Novo Nordisk Investigational Site, Brooklyn
Novo Nordisk Investigational Site, Algiers
Novo Nordisk Investigational Site, Charlottesville
Novo Nordisk Investigational Site, Annaba
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Charlotte
Novo Nordisk Investigational Site, Charleston
Novo Nordisk Investigational Site, El Palmar
Novo Nordisk Investigational Site, Augusta
Novo Nordisk Investigational Site, Macon
Novo Nordisk Investigational Site, Savannah
Novo Nordisk Investigational Site, Gainesville
Novo Nordisk Investigational Site, Orlando
Novo Nordisk Investigational Site, Tampa
Novo Nordisk Investigational Site, Tampa
Novo Nordisk Investigational Site, Bornova-IZMIR
Novo Nordisk Investigational Site, İzmit
Novo Nordisk Investigational Site, Cincinnati
Novo Nordisk Investigational Site, Dayton
Novo Nordisk Investigational Site, Detroit
Novo Nordisk Investigational Site, Samsun
Novo Nordisk Investigational Site, Oak Lawn
Novo Nordisk Investigational Site, Oklahoma City
Novo Nordisk Investigational Site, Salt Lake City
Novo Nordisk Investigational Site, Las Vegas
Novo Nordisk Investigational Site, Long Beach
Novo Nordisk Investigational Site, Sacramento
Novo Nordisk Investigational Site, Portland
Novo Nordisk Investigational Site, Beijing
Novo Nordisk Investigational Site, Beijing
Novo Nordisk Investigational Site, Moscow
Novo Nordisk Investigational Site, Saint Petersburg
Novo Nordisk Investigational Site, Tianjin
Novo Nordisk Investigational Site, Hangzhou
Novo Nordisk Investigational Site, Krasnodar
Novo Nordisk Investigational Site, Chonqqing
Novo Nordisk Investigational Site, Guangzhou
Novo Nordisk Investigational Site, Phoenix
Novo Nordisk Investigational Site, Washington D.C.
Novo Nordisk Investigational Site, New Brunswick
Novo Nordisk Investigational Site, Brooklyn
Novo Nordisk Investigational Site, Klagenfurt
Novo Nordisk Investigational Site, Salzburg
Novo Nordisk Investigational Site, Sankt Pölten
Novo Nordisk Investigational Site, Vienna
Novo Nordisk Investigational Site, Curitiba
Novo Nordisk Investigational Site, Campinas
Novo Nordisk Investigational Site, Athens
Novo Nordisk Investigational Site, Thessaloniki
Novo Nordisk Investigational Site, Shatin, New Territories
Novo Nordisk Investigational Site, Aichi
Novo Nordisk Investigational Site, Hyōgo
Novo Nordisk Investigational Site, Shizuoka
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Vilnius
Novo Nordisk Investigational Site, Bydgoszcz
Novo Nordisk Investigational Site, Lublin
Novo Nordisk Investigational Site, Porto
Novo Nordisk Investigational Site, San Juan
Novo Nordisk Investigational Site, Barcelona
Novo Nordisk Investigational Site, Adana
Novo Nordisk Investigational Site, Antalya
Lead Sponsor
Novo Nordisk A/S
INDUSTRY